306 related articles for article (PubMed ID: 15570574)
41. Remarkable effect of milnacipran in the treatment of Japanese major depressive patients.
Higuchi H; Yoshida K; Takahashi H; Naito S; Tsukamoto K; Kamata M; Ito K; Sato K; Shimizu T
Hum Psychopharmacol; 2002 Jun; 17(4):195-6. PubMed ID: 12404688
[No Abstract] [Full Text] [Related]
42. Discontinuing paroxetine: a personal account.
Shoenberger D
Psychother Psychosom; 2002; 71(4):237-8. PubMed ID: 12097790
[No Abstract] [Full Text] [Related]
43. The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran.
Wakeno M; Kato M; Okugawa G; Fukuda T; Hosoi Y; Takekita Y; Yamashita M; Nonen S; Azuma J; Kinoshita T
J Clin Psychopharmacol; 2008 Oct; 28(5):518-24. PubMed ID: 18794646
[TBL] [Abstract][Full Text] [Related]
44. The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review.
Bruno A; Morabito P; Spina E; Muscatello MR
Curr Neuropharmacol; 2016; 14(2):191-9. PubMed ID: 26572745
[TBL] [Abstract][Full Text] [Related]
45. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.
Rosenbaum JF; Fava M; Hoog SL; Ascroft RC; Krebs WB
Biol Psychiatry; 1998 Jul; 44(2):77-87. PubMed ID: 9646889
[TBL] [Abstract][Full Text] [Related]
46. Therapeutic effects of the selective serotonin noradrenaline reuptake inhibitor milnacipran on depressive symptoms in patients with Alzheimer's disease.
Mizukami K; Hatanaka K; Tanaka Y; Sato S; Asada T
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):349-52. PubMed ID: 19166899
[TBL] [Abstract][Full Text] [Related]
47. Prevalence of induced mania in patients treated with milnacipran: a comparison with paroxetine.
Morishita S; Arita S
Eur Psychiatry; 2004 Aug; 19(5):315-6. PubMed ID: 15276667
[No Abstract] [Full Text] [Related]
48. Discontinuation symptoms and SSRIs.
Pollock BG
J Clin Psychiatry; 1998 Oct; 59(10):535-7. PubMed ID: 9818635
[No Abstract] [Full Text] [Related]
49. FDA questions antidepressant safety for children.
Oransky I
Lancet; 2003 Nov; 362(9395):1558. PubMed ID: 14627000
[No Abstract] [Full Text] [Related]
50. [Serotonin syndrome].
Yamawaki S; Iwamoto Y
Ryoikibetsu Shokogun Shirizu; 2003; (38):370-3. PubMed ID: 12877005
[No Abstract] [Full Text] [Related]
51. Japanese experience with dual-action antidepressants.
Tajima O
Int Clin Psychopharmacol; 2002 Jun; 17 Suppl 1():S37-42. PubMed ID: 12369609
[TBL] [Abstract][Full Text] [Related]
52. [Applications and safety of modern antidepressants in patients with liver diseases].
Dubarek W; Kucia K
Wiad Lek; 2007; 60(1-2):28-33. PubMed ID: 17607965
[TBL] [Abstract][Full Text] [Related]
53. A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder.
Papakostas GI; Fava M
Eur Neuropsychopharmacol; 2007 Jan; 17(1):32-6. PubMed ID: 16762534
[TBL] [Abstract][Full Text] [Related]
54. [Antidepressants with different action mechanisms in the treatment of chronic daily headache].
Amelin AV; Tarasova SV; Ignatov IuD; Skoromets AA; Miatleva MI
Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(9):38-44. PubMed ID: 18379461
[TBL] [Abstract][Full Text] [Related]
55. Therapeutic effects of milnacipran (serotonin noradrenalin reuptake inhibitor) on depression following mild and moderate traumatic brain injury.
Kanetani K; Kimura M; Endo S
J Nippon Med Sch; 2003 Aug; 70(4):313-20. PubMed ID: 12928711
[TBL] [Abstract][Full Text] [Related]
56. Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment.
Shinkai K; Yoshimura R; Ueda N; Okamoto K; Nakamura J
J Clin Psychopharmacol; 2004 Feb; 24(1):11-7. PubMed ID: 14709941
[TBL] [Abstract][Full Text] [Related]
57. New dosage-reduction regime to avoid paroxetine discontinuation syndrome.
Pacheco Yáñez L; Malo P; Etxebeste M; Aragües E; Medrano J
Can J Psychiatry; 2003 Mar; 48(2):129-30. PubMed ID: 12655918
[No Abstract] [Full Text] [Related]
58. Dissecting dementia, depression, and drug effects in older adults.
Sherrod RA; Collins A; Wynn S; Gragg M
J Psychosoc Nurs Ment Health Serv; 2010 Jan; 48(1):39-47. PubMed ID: 20102132
[TBL] [Abstract][Full Text] [Related]
59. Digging for data on harms in duloxetine trials.
Doshi P; Zito J; dosReis S
BMJ; 2014 Jun; 348():g3578. PubMed ID: 24904123
[No Abstract] [Full Text] [Related]
60. Milnacipran for the treatment of chronic pain.
Kamata M; Naito S; Takahashi H; Higuchi H
Hum Psychopharmacol; 2003 Oct; 18(7):575-6. PubMed ID: 14533142
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
